Rhizen receives USFDA orphan drug designation for cancer drug
The US Food and Drug Administration (USFDA) has granted orphan drug designation for Tenalisib (RP6530) for the treatment of patients with peripheral T-cell lymphoma (PTCL), Alembic Pharmaceuticals said in a BSE filing. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 22, 2021 Category: Pharmaceuticals Source Type: news
Moffitt researchers discover potential new drug target to treat cutaneous T cell lymphoma
(H. Lee Moffitt Cancer Center& Research Institute) In order to improve their understanding of how CTCL develops in hopes of developing new therapies, a team of Moffitt scientists conducted a series of studies. In an article published in The Journal of Clinical Investigation, they demonstrate that decreased expression of the protein SATB1 contributes to CTCL development and that drugs that cause SATB1 to become re-expressed may be potential treatment options for this disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 21, 2020 Category: International Medicine & Public Health Source Type: news
PET useful modality in patients with lymphomas
PET imaging can permit more accurate staging in lymphomas, guide treatment,...Read more on AuntMinnie.comRelated Reading:
PET/CT pinpoints Hodgkin's lymphoma treatment response
PET rules out need for radiotherapy in lymphoma patients
Routine PET field-of-view enough for pediatric lymphoma
FDG-PET/CT fails for peripheral T-cell lymphoma outcomes
PET obviates toxic chemo for some Hodgkin's patients (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - December 16, 2020 Category: Radiology Source Type: news
Allogeneic Transplant: Durable Remissions in T-Cell Lymphomas Allogeneic Transplant: Durable Remissions in T-Cell Lymphomas
Five-year progression-free survival approached 40% and 5-year overall survival was over 50% in the study. Treatment-related mortality ranged from about 8% to 24%, depending on the donor type.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 8, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Duvelisib Response Rate'Exciting' in Patients With r/r PTCL Duvelisib Response Rate'Exciting' in Patients With r/r PTCL
Duvelisib is demonstrating encouraging activity and manageable toxicities among patients with relapsed/refractory peripheral T-cell lymphoma (PTCL) in a phase 2 trial.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 8, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
SIMPONI ARIA ® (golimumab) Approved by the U.S. Food and Drug Administration for Active Polyarticular Juvenile Idiopathic Arthritis and Extension of Its Active Psoriatic Arthritis Indication in Patients 2 Years of Age and Older
HORSHAM, PA, September 30, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved SIMPONI ARIA® (golimumab) for patients 2 years of age and older for the treatment of active pJIA and has extended the PsA indication for this same patient population. “This latest FDA approval of SIMPONI ARIA for pediatric use in active pJIA and active PsA not only brings a new option to young patients living with these diseases but also adds to the growing body of evidence for this treatment,” said Mathai Mammen, M.D., Ph.D., Global Head, Jans...
Source: Johnson and Johnson - September 30, 2020 Category: Pharmaceuticals Source Type: news
Extracoporeal photophoresis cost effective in cutaneous T-cell lymphoma
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - May 31, 2020 Category: Drugs & Pharmacology Source Type: news
Continued Treatment with SGX301 in Patients with CTCL Increases Response Rates
SGX301 is being evaluated for the treatment of patients with early-stage cutaneous T-cell lymphoma in the pivotal phase III FLASH study, which demonstrated that continued treatment twice weekly for 12 weeks increased the positive response rate. (Source: CancerNetwork)
Source: CancerNetwork - May 10, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
Soligenix Announces Positive Phase 3 FLASH Study Demonstrates Increased Efficacy with Continued Treatment in Patients with Cutaneous T-Cell Lymphoma
SGX301 treatment response continues to demonstrate highly statistically significant improvement after 12 weeks of therapy
Response rate in patients receiving a total of 12 weeks treatment increased two and a half-fold
Reinforces positive SGX301 prima... Biopharmaceuticals, Oncology Soligenix, synthetic hypericin, cutaneous T-cell lymphoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 30, 2020 Category: Pharmaceuticals Source Type: news
Janssen Announces Submission of Two Applications to U.S. FDA Seeking Approval of SIMPONI ARIA ® (golimumab) for the Treatment of Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis
HORSHAM, PA, April 24, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of two supplemental Biologics License Applications (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of SIMPONI ARIA® (golimumab) for the treatment of polyarticular juvenile idiopathic arthritis (pJIA) and juvenile psoriatic arthritis (jPsA), in patients two years of age and older in combination with methotrexate. If approved for these indications, SIMPONI ARIA would be the first anti-tumor necrosis factor (TNF)-alpha biologic agent administered by intravenous infusion available...
Source: Johnson and Johnson - April 24, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
FDA Grants Fast Track Designation to Tipifarnib to Treat Lymphoma
Kura Oncology ’s leading drug candidate, tipifarnib, was granted fast track designation by the FDA to treat adults of T-cell lymphomas. (Source: CancerNetwork)
Source: CancerNetwork - March 3, 2020 Category: Cancer & Oncology Authors: Matthew Fowler Source Type: news
Old weapon, new target: Dasatinib against angioimmunoblastic T-cell lymphoma
(University of Tsukuba) Researchers from the University of Tsukuba have shown by in vivo experimentation on a mouse model that angioimmunoblastic T-cell lymphoma is highly dependent on T-Cell Receptor Signaling. Further trials also suggest that dasatinib, by targeting the TCR pathway, improved outcomes in both the mouse model and in a clinical trial of five patients who relapsed or were refractory to conventional therapy and therefore showed promise as a candidate drug for AITL treatment. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 28, 2020 Category: International Medicine & Public Health Source Type: news
Discovery could lead to new treatment for rare blood disease
(University of Alberta Faculty of Medicine& Dentistry) A new study shows cancer cells found in the lesions on the skin of cutaneous T-cell lymphoma patients originate from the blood, not the skin as was believed. The protocol to treat the disease was to eliminate the cancer cells from the skin. Based on the findings, researchers believe it would be more effective to treat the malignant clones in the blood rather than waiting until the cells reach the skin and present as lesions. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 27, 2020 Category: Cancer & Oncology Source Type: news
Study Halted;'Hyperprogression' Seen With Nivolumab for R/R PTCL Study Halted;'Hyperprogression' Seen With Nivolumab for R/R PTCL
A phase 2 study suggests the checkpoint inhibitor is not the hoped-for salvage treatment in relapsed or refractory peripheral T-cell lymphoma.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 9, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
NUS researchers discover enzyme's role in 'natural killer T cell lymphoma'
(National University of Singapore) Researchers from the Cancer Science Institute of Singapore uncovered an enzyme which could serve as a potential biomarker for 'natural killer T cell lymphoma' and could lead to new targeting routes for treatment. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 7, 2019 Category: Cancer & Oncology Source Type: news
